The Spanish Ministry of Science and Competitivity has recognized “exceptional contributions to the field of oncology.”
Scientists at IRB Barcelona have produced a dance video that aims to boost awareness of their research into medical advancements, treatments and search for cures, as well as to advance recruitment efforts of new scientists and graduate students, and attract much-needed philanthropic support.
“This is a pioneering initiative in Europe for a centre devoted to basic research. Using a fun, friendly, and community-spirited approach, we highlight the fundamental role that science plays in society’s well-being, and take a look at some of the critical work that we do at IRB,” explains Joan Guinovart, founder and director of the institute, which was set up in 2005.
See video #IRBdances
Catalan biotech Iproteos has won the Expoquimia R+D+I Award in the Biotechnology category for the development of IPR19, a new drug to stop the progression and reverse the cognitive deficits associated with schizophrenia.
The spin-off, founded by two IRB Barcelona scientists leaders in the field of therapeutic peptides, Teresa Tarrago and Ernest Giralt, expect to begin clinical trials of the compound in 2016.
Endowed with € 5,000 in each of their two categories -Biotechnology and Chemistry- the Expoquimia R+D+I Awards were delivered yesterday during the World Chemical Summit Night as part of the Expoquimia Exhibit at the Fair of Barcelona grounds.
The Max-Bergmann-Society, a European-based organization of German, Swiss, and Austrian chemists, seeks to promote peptide research with a special emphasis on chemical methodologies.
Eduard Batlle, ICREA researcher at IRB Barcelona, will head the project “COLOStage”, which has been awarded European funding for technology transfer.
This “Proof of Concept” call has received applications from 128 projects, 28% of which have been granted funding.
Alzheimer’s disease has no cure and virtually no palliative treatments are available. Even today its origin is still unknown. All this has driven the international scientific community to back new approaches that allow early diagnosis of the disease and the discovery of a treatment to stop its progression. IRB Barcelona is not oblivious to this tendency. The researchers Patrick Aloy and Natàlia Carulla head projects addressing an alternative slant on the control and progression of the disease and the discovery of new therapeutic agents.
Twenty-four secondary school students start free year-long course that will allow them to delve into the life sciences.
The course is organised by IRB Barcelona, in collaboration with the Fundació Catalunya-La Pedrera.
Biospain is the main biotechnology event in southern Europe and one of the largest in the world by the number of one-to-one meetings and companies participating.
This year this biennial fair will be held from 24 to 26 September in Santiago de Compostela.
The coordinator of Chemistry and Pharmacology Programme at IRB Barcelona is presented with the Josef Rudinger Memorial Lecture Award during the European Peptide Symposium, in Sofia, Bulgaria.
The award is in recognition of longstanding contributions to the field.
Around 160 scientists, brought together by IRB Barcelona and the BBVA Foundation in a Barcelona Biomed Conference, are discussing the latest research into one of the hallmarks of Alzheimer’s disease, the amyloid-beta protein that is the major component of the plaques that are characteristic of this debilitating disorder.
According to data from Alzheimer's Disease International in 2013, an estimated 135 million people worldwide will be suffering from dementia in 2050, Alzheimer’s disease being the most prevalent. This condition currently affects over 40 million people but is very strongly age-related, giving rise to the prospect of a ‘21st century plague’ affecting the aging populations across the globe.
A recent report from the Cleveland Clinic published in July 3, indicates that 99.6% of the clinical trials for Alzheimer´s disease have failed, with the result that much of the pharmaceutical industry is discouraged and uncertain as to how to proceed. The scientific community, however, is making substantial progress in understand the underlying causes of the disease, an essential factor in the rational design of innovative therapeutic strategies.